Clinical Trial Update: Neoadjuvant Study of Palbociclib in Combination With Letrozole and Trastuzumab in Stage II-III ER+ HER2+ Breast Cancer [Phase 2]

View source ↗

Summary

Phase 2 neoadjuvant trial of palbociclib with letrozole and trastuzumab in stage II-III ER+, HER2+ breast cancer was terminated; results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Letrozole (letrozole)
• Palbociclib (palbociclib)
• Trastuzumab (trastuzumab)

Snippet

Sponsor: Washington University School of Medicine | Conditions: Breast Cancer, Cancer of Breast | Phase 2 | Status: TERMINATED | Results posted: 2021-09-05